Germany launches drug evaluation system, which it considers to be better than NICEBMJ 2009; 339 doi: https://doi.org/10.1136/bmj.b5395 (Published 09 December 2009) Cite this as: BMJ 2009;339:b5395
- Ned Stafford
The research institute that evaluates some new drugs being considered for coverage by Germany’s massive public health insurance system has announced a new evaluation system, which it implies is better than the system employed by the UK’s National Institute for Health and Clinical Excellence (NICE).
The new German system, which evaluates the relation between health benefit of a drug and its cost, was developed by the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne. In cases where potential health benefit of a drug being considered for coverage by public health insurers is not clearly evident, the institute is commissioned by the Federal Joint Committee, Germany’s public health insurance regulator, to undertake an evaluation and give a recommendation.
In an English language press release issued on 30 November, IQWiG director Peter Sawicki says of the news evaluation method: “While our procedure is quite different to that in the UK, there are a lot of similarities with Australia.” The press release, referring to the UK and Germany, also notes: “Moreover, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial